Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Neuropharmacology

• Publication date

  1992-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0028-3908(92)90100-4PMID 1279447
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat

  2005cited by this paper
• Fluoxetine, a selective inhibitor of serotonin uptake

  1991cited by this paper
• Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors.

  1990cited by this paper
• An overview of fluoxetine, a new serotonin-specific antidepressant.

  1989cited by this paper
• Fluoxetine: an alternative to the tricyclics in the treatment of major depression?

  1989cited by this paper
• Effect of fluoxetine pretreatment on plasma and tissue concentrations of desipramine in rats.

  1989cited by this paper
• Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats.

  1989cited by this paper
• Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.

  1988cited by this paper
• Fluoxetine, a Highly Selective Serotonin Reuptake Inhibitor: A Review of Preclinical Studies

  1988cited by this paper
• Fluoxetine enantiomers as antagonists of p-chloroamphetamine effects in rats.

  1986cited by this paper
• Inhibition of serotonin uptake by optical isomers of fluoxetine

  1985cited by this paper
• Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder.

  1985cited by this paper
• Fluoxetine: clinical pharmacology and physiologic disposition.

  1985cited by this paper
• Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors.

  1983cited by this paper
• Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin-comparison of fluoxetine and chlorimipramine.

  1978cited by this paper
• Fluoxetine, a selective serotonin uptake inhibitor

  1978cited by this paper
• Inhibition of serotonin reuptake.

  1977cited by this paper
• A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine.

  1975cited by this paper
• Effect of 3-(p-trifluoromethylphenoxy). N. N. methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine.

  1975cited by this paper
• Comparison of the specificity of 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine and chlorimipramine as amine uptake inhibitors in mice.

  1974cited by this paper

• 19F-{1H} NMR spectroscopy in weakly orienting solvents for the enantiomeric resolution of fluorinated chiral drugs: The case of fluoxetine

  2025cites this paper
• Toxicokinetics of the Antidepressant Fluoxetine and Its Active Metabolite Norfluoxetine in Caenorhabditis elegans and Their Comparative Potency

  2024cites this paper
• Impact of Cytochrome P450 Genetic Variation on Patient-Reported Symptom Improvement and Side Effects Among Children and Adolescents Treated with Fluoxetine

  2024cites this paper
• The impacts of natural product miltirone and the CYP2D6 pharmacogenetic phenotype on fluoxetine metabolism

  2024cites this paper
• Sustainable solutions for direct TLC enantioseparation with in-home thought-out, prepared/modified chiral stationary phases.

  2024cites this paper
• Using integrative samplers to estimate the removal of pharmaceuticals and personal care products in a WWTP and by soil aquifer treatment enhanced with a reactive barrier.

  2023cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

  2023cites this paper
• Spontaneous Resolution of RS-Fluoxetine to a Racemic Conglomerate upon Salt Formation with Oxalic Acid

  2022cites this paper
• Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19

  2022cites this paper
• Chirality of antidepressive drugs: an overview of stereoselectivity

  2022cites this paper
• Potential Role of Adult Hippocampal Neurogenesis in Traumatic Brain Injury.

  2021cites this paper
• Symptomatic and Disease-Modifying Effects of GABAA Receptor Positive Allosteric Modulation in a Mouse Model of Chronic Stress

  2021cites this paper
• Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics

  2020cites this paper
• Ultrasound-assisted dispersive liquid–liquid microextraction coupled with field-amplified capillary electrophoresis for sensitive and quantitative determination of fluoxetine and norfluoxetine enantiomers in biological fluids

  2020cites this paper
• Physiological and behavioral study on depressed rats model treated with Hordeum vulgare extract referenced to SSRI class

  2019cites this paper
• Pharmacokinetic considerations for current state-of-the-art antidepressants

  2019cites this paper
• Detecting fluoxetine and norfluoxetine in wild bird tissues and feathers.

  2019cites this paper
• Computational and experimental studies on the interaction between butyrylcholinesterase and fluoxetine: implications in health and disease

  2018cites this paper
• Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women

  2018cites this paper
• Analytical methodologies for the stereoselective determination of fluoxetine: An overview.

  2018cites this paper
• Applicability evaluation of advanced processes for elimination of neurophysiological activity of antidepressant fluoxetine.

  2018cites this paper
• Enantioselective transformation of fluoxetine in water and its ecotoxicological relevance

  2017cites this paper
• Serotonin toxicity and cytochrome p450 poor metaboliser genotype patient case

  2017cites this paper
• Chirality of Modern Antidepressants: An Overview

  2017cites this paper
• Biodegradation of the steroid progesterone in surface waters

  2017cites this paper
• Analysis of Fluoxetine and Norfluoxetine Enantiomers in Human Plasma and Amniotic Fluid by LC-MS / MS and Its Application to Clinical Pharmacokinetics in Pregnant Women

  2017cites this paper
• Enantioselective quantification of fluoxetine and norfluoxetine by HPLC in wastewater effluents.

  2014cites this paper
• Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.

  2014cites this paper
• An assessment of the risks posed by human pharmaceuticals in the environment to wild birds

  2014cites this paper
• Fluoxetine potentiation of omega-3 fatty acid antidepressant effect: evaluating pharmacokinetic and brain fatty acid-related aspects in rodents.

  2014cites this paper
• Population PK modelling and simulation based on fluoxetine and norfluoxetine concentrations in milk: a milk concentration-based prediction model.

  2014cites this paper
• Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

  2013cites this paper
• Genetic and Epigenetic Factors Affecting Cytochrome P450 Phenotype and Their Clinical Relevance

  2012cites this paper
• Topics on Drug Metabolism

  2012cites this paper
• Sertraline behavioral response associates closer and dose-dependently with cortical rather than hippocampal serotonergic activity in the rat forced swim stress.

  2012cites this paper
• Trace analysis of fluoxetine and its metabolite norfluoxetine. Part II: Enantioselective quantification and studies of matrix effects in raw and treated wastewater by solid phase extraction and liquid chromatography-tandem mass spectrometry.

  2012cites this paper
• Pharmacogenetics of drug-induced birth defects: what is known so far?

  2011cites this paper
• Disposition of Chiral and Racemic Fluoxetine and Norfluoxetine Across Childbearing

  2010cites this paper
• Gas chromatography-mass spectrometry detection of a norfluoxetine artifact in hydrolyzed urine samples may falsely indicate tranylcypromine ingestion.

  2010cites this paper
• Determination of fluoxetine and norfluoxetine enantiomers in human plasma by polypyrrole-coated capillary in-tube solid-phase microextraction coupled with liquid chromatography-fluorescence detection.

  2009cites this paper
• Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex

  2009cites this paper
• Mechanisms by which the serotonergic system inhibits micturition in rats.

  2009cites this paper
• Fluoxetine treatment affects nitrogen waste excretion and osmoregulation in a marine teleost fish.

  2009cites this paper
• Enantioselective Analysis of Fluoxetine and Norfluoxetine by LC in Culture Medium for Application in Biotransformation Studies Employing Fungi

  2009cites this paper
• Fluoxetine treatment affects nitrogen waste excretion and osmoregulation in a marine teleost fish.

  2009cites this paper
• The clinical role of genetic polymorphisms in drug-metabolizing enzymes

  2008cites this paper
• Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.

  2008cites this paper
• Determination of fluoxetine, norfluoxetine and their enantiomers in rat plasma and brain samples by liquid chromatography with fluorescence detection.

  2007cites this paper
• The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants

  2006cites this paper
• Advances in the enantioseparation of second‐generation antidepressant drugs by electrodriven methods

  2006cites this paper
• Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.

  2006cites this paper
• The Complexity of Active Metabolites in Therapeutic Drug Monitoring of Psychotropic Drugs

  2006cites this paper
• Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

  2006cites this paper
• Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.

  2005cites this paper
• and Pharmacodynamics: Selected Classes of Drugs

  2004cites this paper
• Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep.

  2004cites this paper
• Clinical Pharmacology and Therapeuticsof Antidepressants

  2004cites this paper
• Pharmacotherapy of Depression

  2004cites this paper
• Stereoselective pharmacokinetics and placental transfer of fluoxetine and norfluoxetine in pregnant sheep under steady-state conditions

  2004cites this paper
• Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

  2004cites this paper
• Stereospecific Pharmacokinetics and Pharmacodynamics: Selected Classes of Drugs

  2004cites this paper
• Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.

  2003cites this paper
• The development of new antidepressants: focus on duloxetine and escitalopram.

  2003cites this paper
• Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography.

  2003cites this paper
• Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine

  2003cites this paper
• Individualized Medicine - Implementation of Pharmacogenetic Diagnostics in Antidepressant Drug Treatment of Major Depressive Disorders

  2003cites this paper
• Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.

  2002cites this paper
• [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine].

  2002cites this paper
• Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs

  2002cites this paper
• Plasma Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine: Sources of Variability and Preliminary Observations on Relations With Clinical Response

  2002cites this paper
• Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment.

  2002cites this paper
• Current trends in the development of new antidepressants.

  2001cites this paper
• Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523.

  2001cites this paper
• Effect of Alosetron on the Pharmacokinetics of Fluoxetine

  2001cites this paper
• Serum Concentrations of Fluoxetine in the Clinical Treatment Setting

  2001cites this paper
• CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

  2001cites this paper
• Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

  2001cites this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors.

  2000cites this paper
• Chiral high-performance liquid chromatographic analysis of fluoxetine and norfluoxetine in rabbit plasma, urine, and vitreous humor using an acetylated beta-cyclodextrin column.

  2000cites this paper
• Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

  2000cites this paper
• Pharmacokinetics and pharmacodynamics of the selective serotonin reuptake inhibitors, fluoxetine and paroxetine, during pregnancy and the nursing period

  2000cites this paper
• Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.

  1999cites this paper
• The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.

  1999cites this paper
• Chirality and Drugs Used in Psychiatry: Nice to Know or Need to Know?

  1999cites this paper
• Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding

  1999cites this paper
• Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors

  1999cites this paper
• Differential pharmacology of newer antidepressants.

  1998cites this paper
• Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology

  1998cites this paper
• Drug interactions with newer antidepressants: role of human cytochromes P450.

  1998cites this paper
• Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

  1997cites this paper
• Quantification of fluoxetine and norfluoxetine serum levels by reversed-phase high-performance liquid chromatography with ultraviolet detection.

  1997cites this paper
• Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.

  1997cites this paper
• Drug metabolism as a confounding factor in PK/PD population approaches.

  1996cites this paper
• Pharmacology and pharmacokinetics of citalopram and other SSRIs

  1996cites this paper
• Synthesis and 5HT modulating activity of stereoisomers of 3-phenoxymethyl-4-phenylpiperidines.

  1996cites this paper
• Influence of tramadol on neurotransmitter systems of the rat brain.

  1996cites this paper
• Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror

  1995cites this paper
• The use of toxicokinetics for the safety assessment of drugs acting in the brain

  1995cites this paper
• Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.

  1995cites this paper
• Use of peptide combinatorial libraries in drug design: the identification of a potent serotonin reuptake inhibitor derived from a tripeptide cassette library.

  1995cites this paper